

REMARKS

Applicant, through his undersigned representative, appreciates the courtesies extended to the undersigned during a personal interview conducted with Examiner Channavajjala on April 28, 2009. During the aforementioned interview, applicant's representative pointed out that applicant can produce compressed dosage forms (tablets) from guaifenesin compositions under relatively low compressive forces to produce tablets that exhibit low friability, high hardness, and are resistant to capping, citing the last paragraph of the specification.

It was agreed that if applicant amended claim 37 to specify "tablet", as well as a numerical range of "tablet hardness" in place of the phrase "high hardness", that claim 37, and claims dependent thereon would be allowable.

By the foregoing amendment, applicants have so amended claim 37, with support for the hardness values being found in the original disclosure, e.g. Table 2A, Example 2. Accordingly, the application should now be in condition for immediate allowance, which action is earnestly solicited.

For the foregoing reasons, favorable reconsideration and withdrawal of the previous rejection and passage of the application to issue are respectfully requested.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 14-1437, under Order No. 8493.017.US0000

Date: May 5, 2009

Respectfully submitted,



Thomas P. Pavelko
Registration No. 31,689
NOVAK DRUCE & QUIGG LLP
1300 Eye Street, NW
1000 West Tower
Washington, DC 20005
Telephone: (202) 659-0100
Facsimile: (202) 659-0105